Studies of the uricosuric action of the hypolipidemic drug halofenate | Zendy

Ravenscroft Peter J. | Zendy; Sands John M. | Zendy; Emmerson Bryan T. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Studies of the uricosuric action of the hypolipidemic drug halofenate

Author(s) -

Ravenscroft Peter J.,

Sands John M.,

Emmerson Bryan T.

Publication year - 1973

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt1973144part1547

Subject(s) - uricosuric , hypertriglyceridemia , medicine , drug , triglyceride , uric acid , endocrinology , hyperlipidemia , gout , pharmacology , cholesterol , chemistry , hyperuricemia , diabetes mellitus

Six hyperuricemic patients, with a high incidence of hypertriglyceridemia, were placed on a purine‐free maintenance diet during a 2 week single‐blind study of the uricosuric activity of halofenate (MK‐185). In a single dose‐response study, halofenate, given in a dose of 1 gm orally, produced a uricosuric effect of 48 hours' duration and a peak response 6 to 8 hours after administration, with a significant fall in serum urate. In a 3 day trial of the drug, a progressive increase in urate excretion occurred with a further fall in serum urate. During the study, the mean triglyceride concentration fell by 26% and cholesterol by 15% of the pretreatment values.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research